Alumni Ventures Group

Epicore Biosystems, Inc. is a Cambridge, Massachusetts-based company that develops and commercializes a proprietary wearable microfluidic sensing platform designed for athletes. Founded in 2017, the company focuses on analyzing small droplets of sweat directly from the skin to measure a range of health and performance metrics. Its technology allows for non-invasive monitoring of sweat biomarkers, skin health, and physiological states in real-time, facilitating personalized management of hydration, nutrition, and overall health. Epicore's innovative platform is grounded in extensive research in microfluidics and soft materials, aiming to enhance athletic performance and health management through accessible and cost-effective solutions.

TAU Systems develops compact particle accelerators, including advanced laser-based systems and specialized X-ray free-electron lasers. These innovations enable researchers, manufacturers, and medical developers to conduct faster experimentation and accelerate innovation across various scientific and industrial fields.

Springbok Analytics offers an AI-powered software platform that transforms MRIs into three-dimensional analyses of muscle to enable true precision. Springbok Analytics' advanced imaging technology identifies and measures each individual muscle, providing data to scientists, physical therapists, athletic trainers, and physicians to evaluate muscle function in relation to performance and injury management. The technology has numerous applications, including injury management, performance enhancement, and the treatment of musculoskeletal conditions.

Precision Neuroscience is a New York-based neurotechnology company developing a next-generation brain–computer interface platform to enable breakthrough treatments for neurological illnesses affecting billions worldwide. The company aims to deliver minimally invasive, safely removable implants capable of processing large amounts of neural data across multiple brain regions to support therapeutic interventions. Founded in 2021, it focuses on translating neural signals into clinical outcomes, with technology described as a thin-film microelectrode array that conforms to the brain surface without penetrating tissue, enabling broad neural data collection to aid treatment of spinal cord injuries, stroke, and neurodegenerative diseases.

MetaSight Diagnostics, a health technology company, is on a mission to develop affordable and precise liquid biopsy diagnostics for the early detection of a wide range of chronic and acute diseases by leveraging proprietary mass spectrometry technologies (metabolomics, lipidomics, and proteomics).

CytoVale is a medical technology company based in San Francisco that develops biomarkers derived from the mechanical properties of single cells. The company uses microfluidics to route and probe cells, enabling the measurement of multiple biophysical indicators at once. Its technology aims to advance early detection of immune-mediated diseases and sepsis through the analysis of cell mechanics and machine learning. By translating biophysical signals into diagnostic information, CytoVale seeks to improve diagnostic accuracy, support timely treatment decisions, and reduce healthcare costs.

Centaur Labs provides a platform for expert data annotation services, specializing in medical, scientific, and other complex datasets. It leverages a global network of tens of thousands of students and professionals to deliver accurate and scalable solutions.

AminoChain provides a platform that connects data from healthcare organizations to support biosample handling. It enables users to manage biosample inventories, maintain asset ownership, and collaborate with partners through an integrated workflow for procurement, agreements, and payments. The company also applies blockchain-based tokenization to stem cell donations, incentivizing donors and enabling biobanks to securely manage inventory and donor records.

GC Therapeutics employs synthetic biology to transform patient-derived stem cells into diverse cell types efficiently and at scale. The company has validated its technology across multiple applications, creating SuperCells™ tailored for specific conditions. Originally developed in Professor George Church's lab at Harvard Medical School, GC Therapeutics is dedicated to bringing this innovative method to patients.

InGel Therapeutics is a biotechnology company based in Cambridge, Massachusetts, founded in 2021. The company focuses on developing engineered cell therapies aimed at targeting neuroprotective pathways to address retinal degeneration. Utilizing stem cells and their secretome, InGel Therapeutics aims to provide neuroprotection for blinding diseases such as retinitis pigmentosa and macular degeneration. The company leverages biodegradable polymers to isolate neuroprotective proteins, initially testing these solutions in vitro before advancing to in vivo applications. Through its innovative approach, InGel Therapeutics seeks to enable healthcare professionals to more effectively treat patients suffering from retinal degeneration.

Modicus Prime is a developer of advanced computer vision software and self-service artificial intelligence tools focused on the life sciences sector. The company’s innovative platform automates biologics image analysis, addressing critical challenges such as cost, legal, and waste liabilities associated with product quality failures in research and development as well as manufacturing. By integrating heterogeneous life sciences data, Modicus Prime facilitates anomaly detection and monitoring, enhancing decision-making for its clients. The platform empowers users to conduct cutting-edge research, train proprietary algorithms on specific datasets, and utilize self-service tools to derive actionable insights, thereby addressing emerging data challenges in the industry, including continuous manufacturing and smart monitoring.

Magnetic Insight, Inc. is a company specializing in magnetic particle imaging (MPI), an innovative imaging modality that detects iron oxide nanoparticle tracers through time-varying magnetic fields. Founded in 2012 and headquartered in Alameda, California, the company offers several key products, including the MOMENTUM imager, a pre-clinical MPI solution designed to produce high-quality images using advanced magnetic field gradients and proprietary reconstruction processes. Additionally, Magnetic Insight develops VivoTrax, a nanoparticle for cell tracking and as a blood pool agent, and Hyper, an add-on module for the MOMENTUM system that facilitates targeted magnetic hyperthermia treatment. The company's technology enables real-time monitoring of biological events, making significant strides in areas such as quantitative cell tracking, imaging of vascular function, and research into regenerative medicine and CAR-T cell therapies.

An emerging genomic and data science company, developing novel drugs based on naturally occurring resistance mechanisms

Founded in 2016, Bionaut Labs specializes in developing intra-tissue navigation platforms using micro-robots for precise anatomical targeting. Its innovative technology enables remote-controlled delivery of therapeutics to challenging clinical settings, revolutionizing the treatment of central nervous system disorders and other diseases.

ParcelBio is a biotechnology company specializing in the development of a novel, programmable method for safely and precisely delivering messenger RNA (mRNA) to diverse cell types within the body. Their technology aims to create targeted, potent, and durable RNA therapeutics, with the potential to treat a wide range of diseases, including cancer, genetic disorders, and infectious diseases.

Nanochon is developing an implantable, 3D-printed cartilage implant designed to replace damaged cartilage and promote new tissue growth in joints, with a focus on knee damage. The device combines 3D printing and a novel nanomaterial to enable on-demand, cost-effective solutions intended to restore joint function and improve outcomes for young and active patients.

Yoneda Labs is a developer of AI-based software designed to assist chemists in optimizing reaction parameters essential for the synthesis of drugs and materials. The platform enables users to determine critical factors such as temperature, concentration, and catalyst, thereby enhancing the efficiency and speed of chemical laboratory processes. By leveraging advanced artificial intelligence, Yoneda Labs aims to streamline the development of chemical reactions, ultimately facilitating faster innovation in the pharmaceutical and material sciences industries.

Nectero Medical is a clinical-stage biotechnology company based in Dover, Delaware, founded in 2017. The company is focused on developing a novel treatment aimed at stabilizing the growth of mid-sized abdominal aortic aneurysms and preventing their rupture. Nectero Medical's innovative approach involves delivering a compound with a stabilizing agent directly to the aneurysm site, which inhibits further breakdown of the vessel wall and strengthens it. This treatment enables patients to undergo earlier intervention safely, potentially delaying or eliminating the need for major endovascular or surgical repairs.

HelixNano is a biotechnology startup that employs artificial intelligence and synthetic biology to develop innovative treatments for genetic diseases. Founded with backing from Y Combinator and venture capitalists, the company initially focused on creating cancer vaccines over two years. Currently, HelixNano is adapting its technology to combat COVID-19, aiming to produce precise and safe vaccine candidates. Its long-term goal is to develop a universal coronavirus vaccine that protects against future outbreaks.

BE Therapeutics is a biotechnology company specializing in regenerative medicine. It develops innovative therapies aimed at repairing and restoring damaged brain and spinal cord tissue, with the goal of improving patient outcomes for neurological conditions and spinal cord injuries. The company's approach involves engineering functional tissue to replace or repair damaged structures, offering a novel solution in healthcare.

Founded in 2014, Cyrus Biotechnology develops software tools for accelerating basic research in biotech, pharma, and industrial biotechnology. Its flagship product, Cyrus Bench, offers an enterprise version of the Rosetta molecular modeling and design toolkit along with associated bio-molecular computation tools.

Pendulum Therapeutics is a biotechnology company specializing in microbiome-targeted therapies. Founded in 2013 by experts in microbiology, biochemistry, computational science, and clinical research, the company develops evidence-based medical probiotics to manage chronic illnesses, with a focus on type 2 diabetes. Its flagship product, Pendulum Glucose Control, has demonstrated efficacy in lowering blood sugar spikes and reducing A1C levels in clinical trials.

Epicore Biosystems, Inc. is a Cambridge, Massachusetts-based company that develops and commercializes a proprietary wearable microfluidic sensing platform designed for athletes. Founded in 2017, the company focuses on analyzing small droplets of sweat directly from the skin to measure a range of health and performance metrics. Its technology allows for non-invasive monitoring of sweat biomarkers, skin health, and physiological states in real-time, facilitating personalized management of hydration, nutrition, and overall health. Epicore's innovative platform is grounded in extensive research in microfluidics and soft materials, aiming to enhance athletic performance and health management through accessible and cost-effective solutions.

Granata Bio is a biotechnology company established in 2018 that specializes in identifying and developing therapeutics for fertility patients. The company focuses on creating a comprehensive portfolio of fertility-related treatments and leverages its expertise in commercialization, late-stage clinical trials, and regulatory development. Granata Bio aims to address significant challenges faced by medical professionals in fertility treatment. Recently, the company announced a partnership with IBSA Institut Biochimique to co-develop a novel subcutaneous progesterone solution, further enhancing its commitment to improving fertility care.

Earli is a biotechnology company focused on advancing cancer detection and treatment through innovative technology. The company specializes in developing devices that utilize a novel gene therapy approach known as Synthetic Biopsy. This method compels cancer cells to produce synthetic biomarkers, which are not naturally occurring in the human body. These biomarkers can then be detected in bodily fluids such as blood, urine, or breath, allowing for early identification of cancer. By facilitating the early detection of homogeneous tumors, Earli aims to significantly improve the chances of successful treatment and personalize therapy options for patients. Additionally, the technology is designed to be visible during imaging procedures such as PET scans, enhancing the monitoring of cancer progression and treatment efficacy.

Anthology is an evolution company that generates diverse genomes to scale and digitalize biomanufacturing.

Featureform is a company that specializes in developing machine learning tools tailored for the pharmaceutical and biotechnology sectors. It offers an open-source virtual feature store that enables data scientists to define, manage, and serve machine learning features throughout their organizations. The platform provides a unified interface to connect, transform, and join both streaming and batch data, facilitating the discovery and integration of features created by various teams. This functionality allows organizations to share features and enhance their machine learning models. Additionally, Featureform monitors and analyzes these features, offering the capability to freeze them, which allows teams to concentrate on building models that support efficient data pipelines.

Capra Biosciences is a biotechnology company that develops bioreactor technology to enable efficient, low-carbon production of bio-based chemicals. Its biofilm bioreactor platform reduces downstream processing requirements and costs in bio-manufacturing and supports the production of hydrophobic products, including fuels, retinol, and performance lubricants.

CytoVale is a medical technology company based in San Francisco that develops biomarkers derived from the mechanical properties of single cells. The company uses microfluidics to route and probe cells, enabling the measurement of multiple biophysical indicators at once. Its technology aims to advance early detection of immune-mediated diseases and sepsis through the analysis of cell mechanics and machine learning. By translating biophysical signals into diagnostic information, CytoVale seeks to improve diagnostic accuracy, support timely treatment decisions, and reduce healthcare costs.

Jona is a tech startup utilizing artificial intelligence to explore the connection between the microbiome and health. Its platform interprets microbiome tests, providing insights into bacteria, fungi, viruses, and protists, along with associated health conditions, symptoms, food sensitivities, and recommended actions for diet, exercise, sleep, and treatments.

Ummino is a company that specializes in precision fermentation technology aimed at the fortified food and beverage sectors. Founded in 2019 and based in Raleigh, North Carolina, Ummino has developed a method that allows clients to convert common ingredients into high-value functional foods. By unlocking rare compounds found in nature, the company's technology enhances both taste and nutritional value, providing innovative solutions for the food industry.

Eigen Therapeutics is a biotechnology company dedicated to advancing cancer treatment through the development of innovative therapies. It specializes in "priming" therapies that enhance the effectiveness of targeted treatments by addressing cancer heterogeneity, which makes cancer cells more susceptible to therapeutic interventions while simultaneously protecting healthy cells. Eigen is creating a high-throughput discovery platform that integrates proprietary machine learning algorithms to identify novel drug classes and therapeutic approaches capable of altering a cell’s state to increase vulnerability to treatments. This platform combines biology and engineering, utilizing in-house developed robotic systems, laboratory operations software, and machine learning analysis pipelines. The company's mission focuses on improving patient outcomes by providing novel combination therapeutics that enhance efficacy and reduce toxicity in cancer care, ultimately aiming to meet significant medical needs in oncology.

Ruby Bio is a biosynthesis platform that uses naturally occurring yeast to convert low-cost sugar into high-value products. These products are complex molecules that are biodegradable and non-toxic, enabling industries to shift towards full sustainability.

TFC Therapeutics is a biotechnology company focused on creating innovative biologics aimed at addressing critical factors in cancer recurrence and metastasis. The company develops technology that employs monoclonal antibodies designed to specifically bind to receptors on tumor-initiating cells, known as TMH cells. This targeted approach activates the immune system to effectively destroy these cells, offering new treatment possibilities for cancer within the healthcare sector. Through its research and development efforts, TFC Therapeutics seeks to contribute significantly to advancements in cancer therapy.

VenoStent develops bioabsorbable smart polymer wraps for vascular surgeries. Its flagship product, SelfWrap, is a perivascular wrap designed to reduce failures at the vein-artery junction in dialysis patients by promoting outward vein growth and providing custom-fit mechanical support. The company's technology acts as an external stent, reducing surgery time, infection risk, and wound reopening while improving vein usability and durability.

Ossium Health, Inc. is a biotechnology company that specializes in developing and manufacturing advanced cell therapy products aimed at treating blood cancers, improving organ transplantation, and repairing tissue damage caused by radiation exposure. Established in 2016 and based in San Francisco, the company has created a range of therapies, including HPC, Marrow, which consists of human leukocyte antigen (HLA)-matched bone marrow stem cells for hematopoietic reconstitution in blood cancer patients. Additionally, Ossium offers Chimera, designed to enhance organ transplantation, and Chymalis, which utilizes mesenchymal stem cells from bone marrow to facilitate the healing of damaged bone and muscle tissue. The company also supplies bone marrow cells for research in oncology, immunology, and related fields, focusing on improving health and longevity through innovative bioengineering techniques.

3X Genetics is a company focused on developing medical screening solutions aimed at identifying genetic disorders, particularly in infants and children. The company has created innovative technologies that allow for proactive screening of the population for conditions such as myotonic dystrophy and other trinucleotide repeat issues associated with progressive muscle weakness. By enabling healthcare professionals to detect these genetic disorders early, 3X Genetics plays a crucial role in preventing the birth of children affected by serious genetic diseases.

MEND is a life sciences company dedicated to improving health outcomes through targeted clinical nutrition and medical food interventions. The company focuses on researching and developing products that aid in healing from injuries, surgeries, and illness, as well as enhancing physical performance and addressing the challenges of aging. MEND's innovations have gained acceptance in various sectors, including hospitals, health systems, professional sports teams across major leagues, and elite military forces in the United States. The company's commitment to ongoing research and development positions it as a key player in the field of clinical nutritional products, aimed at enabling caregivers to support patients in achieving optimal health and recovery.

Synteny.Ai Syntney decodes the signals of immune repertoires to help biotech research and pharma companies with disease discoveries.

Iolyx Therapeutics is a biotechnology company focused on ocular diseases, developing immunology-driven therapies for ophthalmology and advancing a platform for tailored formulations that enable precise local delivery of immunological drugs to ocular tissues, targeting inflammation at its source in both the anterior and posterior segments to improve efficacy, safety, and patient convenience.

Jona is a tech startup utilizing artificial intelligence to explore the connection between the microbiome and health. Its platform interprets microbiome tests, providing insights into bacteria, fungi, viruses, and protists, along with associated health conditions, symptoms, food sensitivities, and recommended actions for diet, exercise, sleep, and treatments.

Dimension Inx designs and develops advanced biomaterials for regenerative medicine. Founded in 2017, it specializes in creating microenvironments that guide the body's natural healing processes. Its platform focuses on the interplay between material composition, microstructure, and microarchitecture to produce biofunctional materials.

Featureform is a company that specializes in developing machine learning tools tailored for the pharmaceutical and biotechnology sectors. It offers an open-source virtual feature store that enables data scientists to define, manage, and serve machine learning features throughout their organizations. The platform provides a unified interface to connect, transform, and join both streaming and batch data, facilitating the discovery and integration of features created by various teams. This functionality allows organizations to share features and enhance their machine learning models. Additionally, Featureform monitors and analyzes these features, offering the capability to freeze them, which allows teams to concentrate on building models that support efficient data pipelines.

Precision Neuroscience is a New York-based neurotechnology company developing a next-generation brain–computer interface platform to enable breakthrough treatments for neurological illnesses affecting billions worldwide. The company aims to deliver minimally invasive, safely removable implants capable of processing large amounts of neural data across multiple brain regions to support therapeutic interventions. Founded in 2021, it focuses on translating neural signals into clinical outcomes, with technology described as a thin-film microelectrode array that conforms to the brain surface without penetrating tissue, enabling broad neural data collection to aid treatment of spinal cord injuries, stroke, and neurodegenerative diseases.

Gilgamesh Pharmaceuticals, Inc. is a preclinical biotechnology company based in New York, focused on developing innovative psychotropic drugs to address mental health issues. Founded in 2019, the company specializes in creating novel compounds that enhance the benefits of traditional psychedelics, improving parameters such as safety, tolerability, duration, and efficacy. Gilgamesh targets a range of neuropsychiatric conditions, including depression, anxiety, substance use disorders, and stress-related issues. With the growing global mental health crisis, the company aims to accelerate the development of new treatments that meet the urgent need for effective solutions in mental health care, leveraging its expertise in medicinal chemistry and drug development.

Eigen Therapeutics is a biotechnology company dedicated to advancing cancer treatment through the development of innovative therapies. It specializes in "priming" therapies that enhance the effectiveness of targeted treatments by addressing cancer heterogeneity, which makes cancer cells more susceptible to therapeutic interventions while simultaneously protecting healthy cells. Eigen is creating a high-throughput discovery platform that integrates proprietary machine learning algorithms to identify novel drug classes and therapeutic approaches capable of altering a cell’s state to increase vulnerability to treatments. This platform combines biology and engineering, utilizing in-house developed robotic systems, laboratory operations software, and machine learning analysis pipelines. The company's mission focuses on improving patient outcomes by providing novel combination therapeutics that enhance efficacy and reduce toxicity in cancer care, ultimately aiming to meet significant medical needs in oncology.

Modicus Prime is a developer of advanced computer vision software and self-service artificial intelligence tools focused on the life sciences sector. The company’s innovative platform automates biologics image analysis, addressing critical challenges such as cost, legal, and waste liabilities associated with product quality failures in research and development as well as manufacturing. By integrating heterogeneous life sciences data, Modicus Prime facilitates anomaly detection and monitoring, enhancing decision-making for its clients. The platform empowers users to conduct cutting-edge research, train proprietary algorithms on specific datasets, and utilize self-service tools to derive actionable insights, thereby addressing emerging data challenges in the industry, including continuous manufacturing and smart monitoring.

Axoft develops implantable, bioinspired electronics that enable long-term communication with the nervous system to improve clinical outcomes and overall health. The company creates ultra-flexible plastic mesh implants housing multiple sensors that closely match brain tissue mechanics, aiming to reduce tissue response and enable precise monitoring and intervention for neurodegenerative conditions. By enhancing brain–machine communication, Axoft seeks to provide more effective treatments for patients with Parkinson's disease and related disorders, supporting tailored therapies and better patient outcomes.

SURGE Therapeutics is a biotechnology company focused on enhancing cancer treatment outcomes through innovative immunotherapy solutions. It has developed a proprietary injectable biodegradable hydrogel designed to deliver cancer therapeutics in a prolonged and localized manner. This technology enables targeted release of immunotherapy agents at the surgical site following tumor resection, allowing for more effective treatment administration. By optimizing the timing and location of drug delivery, SURGE Therapeutics aims to improve patient survival rates and minimize systemic side effects, representing a significant advancement in the field of cancer care.

Nanopath is a molecular diagnostics company that develops innovative platforms for rapid disease diagnosis. Its technology enables point-of-care testing, eliminating the need for nucleic acid amplification and supporting multiplexed detection. This allows patients and healthcare providers to access accurate diagnostic results within standard office visits, improving healthcare outcomes.

Magnetic Insight, Inc. is a company specializing in magnetic particle imaging (MPI), an innovative imaging modality that detects iron oxide nanoparticle tracers through time-varying magnetic fields. Founded in 2012 and headquartered in Alameda, California, the company offers several key products, including the MOMENTUM imager, a pre-clinical MPI solution designed to produce high-quality images using advanced magnetic field gradients and proprietary reconstruction processes. Additionally, Magnetic Insight develops VivoTrax, a nanoparticle for cell tracking and as a blood pool agent, and Hyper, an add-on module for the MOMENTUM system that facilitates targeted magnetic hyperthermia treatment. The company's technology enables real-time monitoring of biological events, making significant strides in areas such as quantitative cell tracking, imaging of vascular function, and research into regenerative medicine and CAR-T cell therapies.

Swing develops safe and effective digital therapeutics for chronic conditions, partnering with top researchers to create evidence-based treatments. Their solutions empower patients to manage their illnesses, improving health outcomes.

Mozza is a Los Angeles-based company founded in 2018 that specializes in the development of plant-based cheese products. The company aims to create cheese derived from plants that closely replicates the taste and texture of traditional dairy cheese. By utilizing bovine milk proteins, Mozza produces cheese that exhibits the same characteristics as its animal-derived counterparts, including melt, stretch, and flavor. This innovation provides consumers with a viable alternative to dairy cheese, catering to the growing demand for plant-based food options.

Boulder Care, established in 2017 and headquartered in Portland, Oregon, specializes in telemedicine-based programs for opioid addiction treatment. The company offers comprehensive services including medication-assisted treatment with buprenorphine, peer support, patient counseling, and psychosocial services to aid recovery. Boulder Care serves patients directly, as well as healthcare providers and organizations seeking to expand access to effective opioid addiction treatment.

SCiFi Foods is a food technology company focused on developing a sustainable and ethical alternative to conventional meat through the production of cultivated meat. By combining lab-grown meat cells with plant-based ingredients, the company aims to create burgers that closely replicate the taste and sensory experience of traditional beef. SCiFi Foods has achieved significant milestones, including the successful growth of beef cells in suspension, which has the potential to dramatically reduce production costs. Co-founded by CEO Joshua March and CTO Kasia Gora, PhD, the company leverages advanced bioengineering techniques to provide a nutritious and animal-free meat experience. With a commitment to transforming the food landscape, SCiFi Foods has attracted substantial investment from prominent venture capital firms.

Oobli develops healthy, low-calorie protein sweeteners derived from exotic plants. These rare compounds offer great taste without affecting blood sugar levels or gut microbiome. The company has secured regulatory approvals such as FDA 'no questions' letters and GRAS status for multiple proteins.

Legacy is a company focused on transforming male fertility through innovative testing and preservation solutions. Founded by healthcare and fertility experts, Legacy provides home-based kits that allow men to analyze, improve, and preserve their sperm without the need to visit a clinic. Their offerings include sperm analysis and cryogenic storage options, facilitating the preservation of fertility for clients in a straightforward and accessible manner. The company collaborates with leading hospitals, fertility clinics, and progressive employers to ensure high-quality services. Legacy has garnered recognition through various awards, including victories at TechCrunch Disrupt and MassChallenge Boston, and has attracted investment from notable firms such as Bain Capital Ventures and Section 32.

Seaspire Skincare specializes in developing multifunctional colorants and actives inspired by ocean biodiversity. Its flagship product, Xanthochrome, offers broader UV protection and aims to replace harmful ingredients in skincare products, promoting sustainability and reduced adverse effects on human and marine health.

Unicorn Biotechnologies develops a next-generation biomanufacturing platform for cell-based manufacturing, initially focusing on cultivated meat. Its modular bio-reactors, optimized via cloud computing, enable affordable and rapid scaling of production, aiming to improve human health, planetary sustainability, and transition towards animal-free agriculture.

American Gene Technologies International is a gene and cell therapeutics company developing a lentiviral platform for broad applications across infectious diseases, immuno-oncology, monogenic disorders, and regenerative medicine. It pursues HIV cure strategies, including a lead candidate for functional cure, and an immuno-oncology approach that stimulates gamma-delta T cells to target solid tumors. The company also develops a therapeutic approach for Phenylketonuria by expressing phenylalanine hydroxylase, using proprietary viral vector and gene therapy technologies. Founded in 2007 and based in Rockville, Maryland, AGT focuses on translating its platform into therapies that aim to cure diseases rather than merely treat them.

Concerto Biosciences develops microbe-based products that rebuild microbial communities in and around humans and ecosystems. The company uses an ultra-high-throughput platform to experimentally measure millions of microbial interactions and map interaction networks, enabling the discovery of ensembles, which are specific combinations of microbes that work together to shepherd damaged microbial communities back to health. These ensembles have potential applications across medicine and agriculture, addressing global challenges in health, food, and industry. By focusing on microbial community engineering, Concerto aims to become a leading inventor of ensembles and to redefine how microbiomes are leveraged for health and environmental outcomes.

Satellite Bio develops cell therapies and regenerative medicine approaches, spanning cell biology, tissue engineering, and synthetic biology. The company focuses on proprietary, off-the-shelf implantable satellite organs that function as living therapeutic systems to replace or augment critical organ functions in patients with serious diseases, enabling medical professionals to address conditions arising from genetic and environmental factors. Its platform supports the development of modular, scalable therapies aimed at treating complex diseases and transforming patient outcomes.

Epicore Biosystems, Inc. is a Cambridge, Massachusetts-based company that develops and commercializes a proprietary wearable microfluidic sensing platform designed for athletes. Founded in 2017, the company focuses on analyzing small droplets of sweat directly from the skin to measure a range of health and performance metrics. Its technology allows for non-invasive monitoring of sweat biomarkers, skin health, and physiological states in real-time, facilitating personalized management of hydration, nutrition, and overall health. Epicore's innovative platform is grounded in extensive research in microfluidics and soft materials, aiming to enhance athletic performance and health management through accessible and cost-effective solutions.

Verge Genomics is a biotechnology company that uses artificial intelligence and machine learning to accelerate drug discovery for neurodegenerative diseases. The company is founded by experts in machine learning and neuroscience drug development who believe advances in computational genomics can reveal new targets and therapies. Verge Genomics' platform analyzes datasets of any size to identify targets and predict effective drugs, with the aim of delivering treatments that improve patient outcomes while reducing the cost and duration of pharmaceutical development.

Droplette Inc., founded in 2017 and based in Boston, Massachusetts, specializes in innovative skincare technology through its needle-free device designed for the transdermal delivery of active ingredients. This patent-pending system allows for the administration of drugs significantly larger than those achievable with traditional methods, ensuring deep penetration into the skin over large areas. The painless, contact-free device generates no disposables, offering a portable solution for delivering antibiotics to treat serious skin ulcers and infections, thereby minimizing the risks of secondary complications and antibiotic resistance. Additionally, the company is exploring future applications for localized delivery of chemotherapeutics for skin cancer and anti-aging treatments, aiming to enhance skincare routines while avoiding harmful chemicals.

Transcend Therapeutics, Inc., established in 1992 in Waltham, Massachusetts, is a clinical-stage company focused on developing pharmaceuticals to address diseases associated with oxidative stress and tissue damage. The company also specializes in creating psychoactive medicines aimed at treating neuropsychiatric disorders. By targeting specific areas of the brain involved in the pathophysiology of these conditions, Transcend Therapeutics aims to enable healthcare providers to facilitate positive changes in brain function and behavior for their patients.

GRO Biosciences employs computational protein design and synthetic biology to enhance protein therapeutics. It has developed multiple genomically recoded bacterial strains capable of incorporating non-standard amino acids into proteins, resulting in improved potency, stability, and targeted delivery. The company focuses on developing advanced treatments for diabetes, growth disorders, and autoimmunity.

Cellibre, Inc. is a cellular agriculture company founded in 2017 and headquartered in San Diego, California. The company focuses on transforming cells into specialized, sustainable factories to produce significant biological products at scale. Employing an organism-agnostic approach, Cellibre develops natural medicines by leveraging the naturopathic therapies of various cultures, as well as utilizing resources from plants, animals, insects, and marine life. This innovative method enables the healthcare industry to produce cannabinoid-based medicines aimed at providing efficient treatment options.

Founded in 2013, Olaris is dedicated to transforming disease diagnosis and treatment. Utilizing its CEREBRO platform, which integrates metabolomics and machine learning, the company discovers and develops precision diagnostics under its myOLARIS™ brand.

Founded in 2014, Cyrus Biotechnology develops software tools for accelerating basic research in biotech, pharma, and industrial biotechnology. Its flagship product, Cyrus Bench, offers an enterprise version of the Rosetta molecular modeling and design toolkit along with associated bio-molecular computation tools.

Veralox Therapeutics specializes in the development of small molecule therapeutics aimed at addressing the underlying pathologies of thrombosis and type one diabetes. The company focuses on innovative treatment paradigms informed by a deep understanding of the molecular mechanisms involved in these diseases. By targeting conditions such as heparin-induced thrombocytopenia and thrombosis, Veralox Therapeutics aims to enhance patient outcomes and facilitate complete recovery from diabetes. Through its research and development efforts, the company seeks to provide effective and transformative therapies for individuals affected by these serious health conditions.

Strateos specializes in automating chemistry, biology, and tissue analysis in closed-loop robotic labs, accelerating drug discovery programs for pharmaceutical partners. By combining advanced robotics, software for imaging and analytics, and remote cloud laboratories, Strateos enables more rapid and efficient discovery of new drug candidates. The company was formed through a merger of Transcriptic, which developed the first robotic cloud laboratory platform for life science research, and 3Scan, which specialized in automating tissue analysis. Strateos aims to express life science methods as data, enabling infrastructure virtualization and driving the next generation of discovery with significant time and cost efficiencies.

miRecule is a biotechnology company developing targeted RNA therapies for cancer and muscular dystrophy. It uses its proprietary DREAmiR platform to analyze genomic data from thousands of patients, identifying genetic abnormalities and creating tailored RNA therapeutics to directly address these issues.

Prima is a science-backed whole-body wellness brand that develops potent plant-based skincare, body care and supplements using organic hemp CBD and functional botanicals to address stress and target issues at their source. Its products emphasize purity, potency and transparency, drawing on clinically studied plant ingredients. Built on sustainability, transparency and accountability, Prima holds Climate Neutral, Plastic Neutral and B Corp certifications. Based in Santa Monica, California, Prima bridges science and nature through education, social impact and innovative botanical products that support health, happiness and well-being.

Gilgamesh Pharmaceuticals, Inc. is a preclinical biotechnology company based in New York, focused on developing innovative psychotropic drugs to address mental health issues. Founded in 2019, the company specializes in creating novel compounds that enhance the benefits of traditional psychedelics, improving parameters such as safety, tolerability, duration, and efficacy. Gilgamesh targets a range of neuropsychiatric conditions, including depression, anxiety, substance use disorders, and stress-related issues. With the growing global mental health crisis, the company aims to accelerate the development of new treatments that meet the urgent need for effective solutions in mental health care, leveraging its expertise in medicinal chemistry and drug development.

Scipher Medicine develops a molecular technology platform that predicts patient responsiveness to specific drugs in cardiovascular and autoimmune diseases. Its flagship product, PrismRA, identifies rheumatoid arthritis patients unlikely to respond to anti-TNF therapies, enabling alternative treatments. The company aims to transform drug prescription by predicting optimal therapy using simple blood samples.

InteRNA Technologies B.V. is a biotechnology company focused on developing microRNA (miRNA)-based therapeutics for cancer treatment. Founded in 2006 and headquartered in Nijmegen, the Netherlands, with a research and development center in Utrecht, the company leverages its proprietary technology to discover and validate miRNA sequences that can target multiple signaling pathways involved in cancer initiation, progression, and metastasis. By addressing previously undruggable targets, InteRNA aims to enhance the efficacy of existing cancer therapies and reduce the development of drug resistance. The company employs advanced bioinformatics and massively parallel sequencing techniques to analyze miRNA functions, paving the way for innovative treatment options in oncology.

STIMIT AG is a medtech company based in Nidau, Switzerland, established in 2018. The company specializes in developing innovative therapies and medical devices aimed at patients who have lost their natural breathing function, particularly those on mechanical ventilation. STIMIT's proprietary technology non-invasively activates the body's own diaphragm, which is often weakened in such patients. By strengthening diaphragm function, the company seeks to facilitate the liberation of patients from ventilators, thereby reducing the time spent on ventilation and improving overall patient outcomes. Additionally, STIMIT is working on second-generation therapies that aim to further enhance the inhalation process for patients. Through these advancements, STIMIT is positioned to significantly impact intensive care practices and improve the quality of life for patients with respiratory challenges.

Concerto Biosciences develops microbe-based products that rebuild microbial communities in and around humans and ecosystems. The company uses an ultra-high-throughput platform to experimentally measure millions of microbial interactions and map interaction networks, enabling the discovery of ensembles, which are specific combinations of microbes that work together to shepherd damaged microbial communities back to health. These ensembles have potential applications across medicine and agriculture, addressing global challenges in health, food, and industry. By focusing on microbial community engineering, Concerto aims to become a leading inventor of ensembles and to redefine how microbiomes are leveraged for health and environmental outcomes.

Cultured Decadence is a cellular aquaculture startup based in Madison, Wisconsin, founded in 2020. The company specializes in innovative methods to produce crustacean products, specifically focusing on lobster and crab meat. Utilizing cell culture and tissue engineering techniques, Cultured Decadence creates seafood directly from the cells of these animals, eliminating the need for shells, organs, and waste. This approach aims to address the increasing global demand for nutritious and sustainable seafood, providing a more environmentally friendly alternative to traditional fishing practices.

Unlearn.AI, Inc. is a biotechnology company based in San Francisco, California, that specializes in developing innovative software tools for clinical research. Established in 2017, Unlearn.AI focuses on enhancing clinical trials through its unique digital twin technology, known as TwinRCT. This approach utilizes machine learning to create prognostic digital twins for individual patients, allowing for more accurate estimations of treatment effects while reducing the number of participants needed. The company also offers services for Clinical Trial Design, which helps determine inclusion criteria, endpoints, and study sizes, as well as Synthetic Control Arms that can minimize or eliminate the need for concurrent control groups. Additionally, Unlearn.AI provides Subgroup Analysis to identify and analyze specific patient subgroups within trial results. By integrating expertise from pharmaceuticals, medical technology, and machine learning, Unlearn.AI aims to transform clinical trials to improve outcomes for both patients and sponsors.

Ionobell is a battery technology developer specializing in improving battery longevity and performance using eco-friendly materials. They focus on utilizing biomaterials, plastic waste, and recycled materials to create safe, abundant, and cost-effective batteries for electric vehicles and unmanned aerial vehicles.

Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapeutics through its pioneering platform in Generative Biology. Established in 2018, the company utilizes machine learning to analyze existing proteins, enabling it to understand the principles governing the relationship between genetic sequences and protein structure. This approach facilitates the invention of novel antibodies, peptides, enzymes, receptors, and other protein-based therapeutics optimized for specific biological functions. By harnessing its advanced technology, Generate Biomedicines aims to accelerate drug discovery by generating new biological molecules with significant therapeutic potential. Originally known as Generate Biologics, the company adopted its current name in March 2020 to reflect its expanded focus on biomedicine.

Brio Systems provides a turnkey COVID-19 testing platform for employers, linking laboratories and medical suppliers with workplaces to enable on-site testing. Its platform supports PCR and antibody testing conducted by FDA-certified laboratories, manages logistics for kit distribution and test requisitioning, provides medical oversight, and delivers digital results within about three days of collection. It serves customers across manufacturing, food processing, and other industries, offering a scalable solution that can support up to 50,000 tests daily. Founded in 2017 and based in Boston, Brio Systems focuses on helping employers maintain workforce safety and business continuity through data-driven testing programs.

Oobli develops healthy, low-calorie protein sweeteners derived from exotic plants. These rare compounds offer great taste without affecting blood sugar levels or gut microbiome. The company has secured regulatory approvals such as FDA 'no questions' letters and GRAS status for multiple proteins.

SCiFi Foods is a food technology company focused on developing a sustainable and ethical alternative to conventional meat through the production of cultivated meat. By combining lab-grown meat cells with plant-based ingredients, the company aims to create burgers that closely replicate the taste and sensory experience of traditional beef. SCiFi Foods has achieved significant milestones, including the successful growth of beef cells in suspension, which has the potential to dramatically reduce production costs. Co-founded by CEO Joshua March and CTO Kasia Gora, PhD, the company leverages advanced bioengineering techniques to provide a nutritious and animal-free meat experience. With a commitment to transforming the food landscape, SCiFi Foods has attracted substantial investment from prominent venture capital firms.

Unlearn.AI, Inc. is a biotechnology company based in San Francisco, California, that specializes in developing innovative software tools for clinical research. Established in 2017, Unlearn.AI focuses on enhancing clinical trials through its unique digital twin technology, known as TwinRCT. This approach utilizes machine learning to create prognostic digital twins for individual patients, allowing for more accurate estimations of treatment effects while reducing the number of participants needed. The company also offers services for Clinical Trial Design, which helps determine inclusion criteria, endpoints, and study sizes, as well as Synthetic Control Arms that can minimize or eliminate the need for concurrent control groups. Additionally, Unlearn.AI provides Subgroup Analysis to identify and analyze specific patient subgroups within trial results. By integrating expertise from pharmaceuticals, medical technology, and machine learning, Unlearn.AI aims to transform clinical trials to improve outcomes for both patients and sponsors.

Endless West is a beverage company that produces wine and spirits using molecular science. It creates original blends by extracting taste, smell, and color molecules from various natural sources, eliminating the need for grapes or fermentation. The company's first product, Glyph, is an aged-style spirit made without aging or barreling, resulting in significant water and land savings.

Brio Systems provides a turnkey COVID-19 testing platform for employers, linking laboratories and medical suppliers with workplaces to enable on-site testing. Its platform supports PCR and antibody testing conducted by FDA-certified laboratories, manages logistics for kit distribution and test requisitioning, provides medical oversight, and delivers digital results within about three days of collection. It serves customers across manufacturing, food processing, and other industries, offering a scalable solution that can support up to 50,000 tests daily. Founded in 2017 and based in Boston, Brio Systems focuses on helping employers maintain workforce safety and business continuity through data-driven testing programs.

Mission Bio develops and delivers tools for studying cellular heterogeneity in human health and life science research. Its flagship product is the Tapestri Platform, a single-cell platform that detects DNA and protein changes, enabling precise detection of heterogeneity in disease progression and treatment response. The company's solutions are primarily applied in oncology, including blood cancers and solid tumors.

Emulate is a biotechnology company that develops organ-on-a-chip human emulation technology to model how diseases, medicines, chemicals, and foods affect human health. Its platform includes lung, intestinal, liver, and skin organ chips that reproduce normal biology and disease states, enabling human-relevant insights beyond traditional cell culture or animal models. The company also provides drug development tools and instrumentation software to support research and development workflows for researchers across biotechnology, pharmaceutical, consumer health, cosmetics, chemical, food, and agrochemical sectors, as well as government agencies and academic institutions. Founded in 2013 and headquartered in Boston, Emulate aims to accelerate understanding of human biology and improve human health outcomes.

Emulate is a biotechnology company that develops organ-on-a-chip human emulation technology to model how diseases, medicines, chemicals, and foods affect human health. Its platform includes lung, intestinal, liver, and skin organ chips that reproduce normal biology and disease states, enabling human-relevant insights beyond traditional cell culture or animal models. The company also provides drug development tools and instrumentation software to support research and development workflows for researchers across biotechnology, pharmaceutical, consumer health, cosmetics, chemical, food, and agrochemical sectors, as well as government agencies and academic institutions. Founded in 2013 and headquartered in Boston, Emulate aims to accelerate understanding of human biology and improve human health outcomes.

Gallant Pet, Inc. is a pet service company based in San Diego, California, that specializes in stem cell preservation services for pets. Founded in 2018 by Aaron Hirschhorn, the company collects and banks stem cells from tissue during routine spay or neuter procedures. Gallant Pet also provides a platelet-rich plasma (PRP) kit for treatment of dogs suffering from osteoarthritis or other musculoskeletal conditions. In addition to its preservation services, Gallant Pet is involved in clinical research to develop effective stem cell therapies for pets. The company's focus on retrieving and preserving regenerative cells allows pet owners to utilize their pets' young stem cells for potential treatments when needed.

Excision BioTherapeutics Inc. is a life science company based in Philadelphia, Pennsylvania, established in 2015. The company is dedicated to the development and commercialization of gene editing therapeutics aimed at treating life-threatening diseases caused by neurotropic viruses. Utilizing CRISPR-based technology, Excision BioTherapeutics focuses on creating advanced gene-editing medicines that can eradicate or disrupt viral genes in human patients. The company's mission is to advance these therapeutics into safe and effective treatments, significantly improving the lives of individuals affected by viral infections globally.

SQZ Biotech is a clinical-stage biotechnology company focused on developing innovative cell therapies for cancer, infectious diseases, and other serious health conditions. Utilizing its proprietary CellSqueeze technology, the company can deliver a variety of materials into diverse patient cell types, enabling the engineering of therapies that address a wide range of clinical challenges. SQZ Biotech aims to create well-tolerated and effective cell therapies that enhance patient experiences compared to traditional approaches. With its commitment to internal research and strategic partnerships, SQZ is working to advance a new generation of cell therapies through both immune activation and immune suppression methods, showcasing its potential to transform treatment options for patients.

miRecule is a biotechnology company developing targeted RNA therapies for cancer and muscular dystrophy. It uses its proprietary DREAmiR platform to analyze genomic data from thousands of patients, identifying genetic abnormalities and creating tailored RNA therapeutics to directly address these issues.

Allevi is a pioneering company that develops innovative tools for designing and engineering 3D tissues. It specializes in desktop 3D bioprinters capable of creating functional, three-dimensional living tissues, alongside proprietary bioinks composed of collagen and hyaluronic acid. Allevi's cloud-based platform, Bioprint Online, allows users to design structures, select materials, and monitor the printing process. Its products cater to a diverse clientele, including researchers in tissue engineering, regenerative medicine, material science, and cell biology, as well as industrial and pharmaceutical companies involved in drug testing and development. Additionally, Allevi sells its bioinks online. Founded in 2014 and headquartered in Philadelphia, Pennsylvania, the company was previously known as BioBots, Inc.

Founded in 2013, Olaris is dedicated to transforming disease diagnosis and treatment. Utilizing its CEREBRO platform, which integrates metabolomics and machine learning, the company discovers and develops precision diagnostics under its myOLARIS™ brand.

E25Bio Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2018, that focuses on developing rapid diagnostic tests for epidemic fever viruses. The company designs paper-based diagnostic systems and kits that facilitate the detection of viruses such as dengue, chikungunya, and Zika. E25Bio's innovative platform enables multiplexed testing that quickly identifies viral antigens during infections, allowing for real-time data reporting through a mobile application. This capability supports epidemiologic predictions and disease mapping, empowering governments and health organizations to respond effectively to outbreaks and manage public health crises. Through its commitment to fast, mobile testing solutions, E25Bio aims to prevent severe health outcomes associated with viral epidemics.

Motif FoodWorks, Inc. is a bio-organism engineering company based in Boston, Massachusetts, that specializes in developing innovative food ingredients. The company focuses on producing animal-free proteins, including meat alternatives and dairy-free proteins, catering to the growing demand for plant-based food solutions. By utilizing fermentation technology, Motif creates essential proteins and nutrients that enhance both nutrition and flavor in food products. The company collaborates with chefs, health experts, and food innovators to develop new ingredient solutions aimed at transforming the food industry and promoting sustainability. Established in 2018 and originally known as Motif Ingredients, Motif FoodWorks rebranded in 2019 to reflect its commitment to advancing the next generation of healthy and plant-based foods.